Tyrosine kinase inhibition: Ligand binding and conformational change in c-Kit and c-Abl

FEBS Letters

Volumn 583, Issue 17, 2009, Pages 2899-2906

  Healy, Eamonn F ^a   Johnson, Skylar ^a   Hauser, Charles R ^a   King, Peter J ^a  

^a ST EDWARD'S UNIVERSITY   (United States)

Author keywords

c Abl; c Kit; Docking; Ellipticine; Imatinib mesylate; Molecular dynamics

Indexed keywords

ABELSON KINASE; IMATINIB; STEM CELL FACTOR RECEPTOR;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG BINDING; ENZYME INHIBITION; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; QUANTUM MECHANICS;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; ELLIPTICINES; ENZYME ACTIVATION; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; SEQUENCE ALIGNMENT; WATER;

EID: 69249240169     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.07.051     Document Type: Article

References (28)

1. Mauro M.J., and Druker B.J. STI571: targeting BCR-ABL as therapy for CML. Oncologist 6 (2001) 230-232
2. Heinrich M.C., Griffith D.J., Druker B.J., Wait C.L., Ott K.A., and Zigler A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96 (2000) 925-932
3. Kerkelä R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J., and Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12 (2006) 908-916
4. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 7 (2006) 358-364
5. O'Hare T., Walters D.K., Stoffregen E.P., Sherbenou D.W., Heinrich M.C., Deininger M.W., and Druker B.J. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 11 (2005) 6987-6993
6. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., McGreevey L.S., Chen C.J., Van den Abbeele A.D., Druker B.J., Kiese B., Eisenberg B., Roberts P.J., Singer S., Fletcher C.D., Silberman S., Dimitrijevic S., and Fletcher J.A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21 (2003) 4342-4349
7. Liao J.J.-L. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J. Med. Chem. 50 (2007) 409-424
8. Bikker J.A., Brooijmans N., Wissner A., and Mansour T.S. Kinase domain mutations in cancer: implications for small molecule drug design strategies. J. Med. Chem. 52 (2009) 1493-1509
9. Schindler T., Bornmann W., Pellicena P., Miller W.T., Clarkson B., and Kuriyan J. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289 (2000) 1938-1942
10. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., Snell G.P., Zou H., Sang B.C., and Wilson K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
11. Levinson N.M., Kuchment O., Shen K., Young M.A., Koldobskiy M., Karplus M., Cole P.A., and Kuriyan J. A Src-like inactive conformation in the Abl tyrosine kinase domain. PLoS Biol. 4 (2006) e144
12. Chen H., Ma J., Li W., Eliseenkova A.V., Xu C., Neubert T.A., Miller W.T., and Mohammadi M. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol. Cell. 27 (2007) 717-730
13. Kan S.H., Elanko N., Johnson D., Cornejo-Roldan L., Cook J., Reich E.W., Tomkins S., Verloes A., Twigg S.R., and Rannan-Eliya S. Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis. Am. J. Hum. Genet. 70 (2002) 472-486
14. de Ravel T.J., Taylor I.B., Van Oostveldt A.J., Fryns J.P., and Wilkie A.O. A further mutation of the FGFR2 tyrosine kinase domain in mild Crouzon syndrome. Eur. J. Hum. Genet. 13 (2005) 503-505
15. Fernández A., and Scott R. Dehydron: a structurally encoded signal for protein interaction. Biophys. J. 85 (2003) 1914-1928
16. Fernández A., and Scheraga H. Insufficiently dehydrated hydrogen bonds as determinants of protein interactions. Proc. Natl. Acad. Sci. USA 100 (2003) 113-118
17. Fernández A., Sanguino A., Peng Z., Crespo A., Ozturk E., Zhang X., Wang S., Bornmann W., and Lopez-Berestein G. Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res. 67 (2007) 4028-4033
18. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., Clarkson B., Superti-Furga G., and Kuriyan J. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
19. Mol C.D., Lim K.B., Sridhar V., Zou H., Chien E.Y.T., Sang B.-C., Nowakowski J., Kassel D.B., Cronin C.N., and McRee D.E. Structure of a c-Kit Product complex reveals the basis for kinase transactivation. J. Biol. Chem. 278 (2003) 31461-31464
20. Wu G., Robertson D.H., Brooks III C.L., and Vieth M. Detailed analysis of grid-based molecular docking: a case study of CDOCKER - a CHARMm-based MD docking algorithm. J. Comput. Chem. 24 (2003) 1549-1562
21. Venkatachalam C.M., Jiang X., Oldfield T., and Waldman M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J. Mol. Graph. Model. 21 (2003) 289-307
22. Honig B., and Nicholls A. Classical electrostatics in biology and chemistry. Science 268 (1995) 1144-1149
23. Dewar M.J.S., Zoebisch E.G., Healy E.F., and Stewart J.J.P. AM1: a new general purpose quantum mechanical molecular model. J. Am. Chem. Soc. 107 (1985) 3902-3909
24. Klamt A. Conductor-like screening model for real solvents: a new approach to the quantitative calculation of solvation phenomena. J. Phys. Chem. 99 (1995) 2224-2235
25. Do C.B., Mahabhashyam M.S., Brudno M., and Batzoglou S. ProbCons: probabilistic consistency-based multiple sequence alignment. Genome Res. 15 (2005) 330-340
26. Maddipati S., and Fernández A. Feature-similarity protein classifier as a ligand engineering tool. Biomol Eng. 23 (2006) 307-315
27. Vendôme J., Letard S., Martin F., Svinarchuk F., Dubreuil P., Auclair C., and Le Bret M. Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J. Med. Chem. 48 (2005) 6194-6201
28. Yang S., and Roux B. Src kinase conformational activation: thermodynamics, pathways, and mechanisms. PLoS Comput. Biol. 4 (2008) e1000047